Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
QTTB Stock Forecast 2026-2027
$18.46
Current Price
$313.02M
Market Cap
Buy 4
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to QTTB Price Targets
+8.3%
To High Target of $20.00
-26.9%
To Median Target of $13.50
-45.8%
To Low Target of $10.00
QTTB Price Momentum
+31.1%
1 Week Change
+43.5%
1 Month Change
+787.5%
1 Year Change
+456.0%
Year-to-Date Change
-21.7%
From 52W High of $23.57
+1,076.5%
From 52W Low of $1.57
📊 TOP ANALYST CALLS
Did QTTB Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Q32 Bio is one of their latest high-conviction picks.
Latest QTTB Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, QTTB has a bullish consensus with a median price target of $13.50 (ranging from $10.00 to $20.00). The overall analyst rating is Strong Buy (9.2/10). Currently trading at $18.46, the median forecast implies a -26.9% downside. This outlook is supported by 4 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
QTTB Analyst Ratings
4
Buy
1
Hold
0
Sell
QTTB Price Target Range
Low
$10.00
Average
$13.50
High
$20.00
Current: $18.46
Latest QTTB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for QTTB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 22, 2026 | Mizuho | Joseph Catanzaro | Outperform | Initiates | $14.00 |
| May 18, 2026 | Cantor Fitzgerald | Overweight | Initiates | $N/A | |
| May 5, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Feb 25, 2026 | HC Wainwright & Co. | Buy | Initiates | $N/A | |
| Mar 12, 2025 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| Feb 11, 2025 | BMO Capital | Market Perform | Downgrade | $N/A | |
| Feb 11, 2025 | Piper Sandler | Neutral | Downgrade | $N/A | |
| Dec 12, 2024 | BMO Capital | Outperform | Maintains | $N/A | |
| Dec 12, 2024 | Guggenheim | Neutral | Downgrade | $N/A | |
| Dec 11, 2024 | Oppenheimer | Outperform | Maintains | $N/A | |
| Dec 11, 2024 | Piper Sandler | Overweight | Maintains | $N/A | |
| Dec 11, 2024 | Wells Fargo | Equal-Weight | Downgrade | $N/A | |
| Dec 11, 2024 | Leerink Partners | Market Perform | Downgrade | $N/A | |
| Dec 11, 2024 | Raymond James | Outperform | Downgrade | $N/A | |
| Dec 6, 2024 | BMO Capital | Outperform | Initiates | $N/A | |
| Oct 24, 2024 | Raymond James | Strong Buy | Initiates | $N/A | |
| Sep 11, 2024 | Wells Fargo | Overweight | Initiates | $N/A | |
| Jun 17, 2024 | Guggenheim | Buy | Initiates | $N/A | |
| May 21, 2024 | Leerink Partners | Outperform | Initiates | $N/A | |
| Apr 11, 2024 | Oppenheimer | Outperform | Initiates | $N/A |
Q32 Bio Inc. (QTTB) Competitors
The following stocks are similar to Q32 Bio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Q32 Bio Inc. (QTTB) Financial Data
Q32 Bio Inc. has a market capitalization of $313.02M with a P/E ratio of 4.0x. The company generates $53.74M in trailing twelve-month revenue with a 61.9% profit margin.
Revenue growth is -100.0% quarter-over-quarter, while maintaining an operating margin of +39.8% and return on equity of +157.2%.
Valuation Metrics
Market Cap
$313.02M
Enterprise Value
$152.98M
P/E Ratio
4.0x
PEG Ratio
-0.1x
Price/Sales
3.5x
Growth & Margins
Revenue Growth (YoY)
-100.0%
Gross Margin
N/A
Operating Margin
+39.8%
Net Margin
+61.9%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+16.2%
Current Ratio
5.4x
Debt/Equity
29.5x
ROE
+157.2%
ROA
+18.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Q32 Bio Inc. (QTTB) Business Model
About Q32 Bio Inc.
What They Do
Develops biologic therapeutics for immune diseases.
Business Model
Q32 Bio Inc. operates as a clinical-stage biotechnology company, generating revenue through the development and commercialization of innovative antibody-based therapies targeting autoimmune and inflammatory diseases. The company is currently focused on its lead candidate, bempikibart (ADX-914), which is undergoing clinical trials, and has previously monetized its assets by selling another candidate while retaining its underlying platform.
Additional Information
Headquartered in Waltham, Massachusetts, Q32 Bio was founded in 2017. The company aims to address unmet medical needs in immune-mediated conditions, with a pipeline that includes additional therapies like ADX-096 for potential ophthalmologic indications and various C3d mAb fusions and nanobodies for complement inhibition.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
42
CEO
Ms. Jodie Pope Morrison
Country
United States
IPO Year
N/A
Website
www.q32bio.comQ32 Bio Inc. (QTTB) Latest News & Analysis
Latest News
Quick Summary
Q32 Bio Inc. (NASDAQ:QTTB) shares rose following positive 36-week topline results from Part B of its Phase 2a SIGNAL-AA trial.
Why It Matters
Positive trial results can indicate potential for drug approval, boosting Q32 Bio's market value and attractiveness to investors seeking growth in biotech stocks.
Source: Benzinga
Market Sentiment:
Positive
Quick Summary
Q32 Bio's bempikibart shows a 35.3% mean reduction in SALT score for alopecia areata, with 40% achieving SALT-20 response at Week 36. The company plans a registration program by mid-2027.
Why It Matters
Positive efficacy data for bempikibart in treating alopecia areata enhances its development prospects, potentially boosting Q32 Bio's stock value and attracting investor interest.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
U.S. stock futures are trading lower this morning. Investors may focus on specific stocks today as market conditions evolve.
Why It Matters
Lower U.S. stock futures indicate market uncertainty, potentially signaling volatility. Investors may shift attention to specific stocks for opportunities or risk management.
Source: Benzinga
Market Sentiment:
Neutral
Quick Summary
A conference call is scheduled for July 13 at 8:00 a.m. E.T. in Waltham, Massachusetts. Investors may want to tune in for updates.
Why It Matters
The scheduled conference call may provide insights into company performance or strategy, influencing stock price and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Q32 Bio Inc. has secured a $55 million private placement of common stock and pre-funded warrants from institutional and accredited investors.
Why It Matters
Q32 Bio's $55 million private placement indicates strong investor confidence and provides necessary capital for advancing therapies, potentially impacting share value and future growth prospects.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Q32 Bio (QTTB) is rated 'Buy' as it advances bempikibart for Alopecia Areata. Catalysts include mid-2026 data from its phase 2a trial, with funding extending cash runway to 1H 2028.
Why It Matters
Q32 Bio's 'Buy' rating signals confidence in its bempikibart trial for Alopecia Areata, with promising data timelines and sufficient funding to reach key milestones, suggesting growth potential.
Source: Seeking Alpha
Market Sentiment:
Positive
Frequently Asked Questions About QTTB Stock
What is Q32 Bio Inc.'s (QTTB) stock forecast for 2027?
Based on our analysis of 2 Wall Street analysts, Q32 Bio Inc. (QTTB) has a median price target of $13.50. The highest price target is $20.00 and the lowest is $10.00.
Is QTTB stock a good investment in 2027?
According to current analyst ratings, QTTB has 4 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $18.46. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for QTTB stock?
Wall Street analysts predict QTTB stock could reach $13.50 in the next 12 months. This represents a -26.9% decrease from the current price of $18.46. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Q32 Bio Inc.'s business model?
Q32 Bio Inc. operates as a clinical-stage biotechnology company, generating revenue through the development and commercialization of innovative antibody-based therapies targeting autoimmune and inflammatory diseases. The company is currently focused on its lead candidate, bempikibart (ADX-914), which is undergoing clinical trials, and has previously monetized its assets by selling another candidate while retaining its underlying platform.
What is the highest forecasted price for QTTB Q32 Bio Inc.?
The highest price target for QTTB is $20.00 from at , which represents a 8.3% increase from the current price of $18.46.
What is the lowest forecasted price for QTTB Q32 Bio Inc.?
The lowest price target for QTTB is $10.00 from at , which represents a -45.8% decrease from the current price of $18.46.
What is the overall QTTB consensus from analysts for Q32 Bio Inc.?
The overall analyst consensus for QTTB is bullish. Out of 2 Wall Street analysts, 4 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $13.50.
How accurate are QTTB stock price projections?
Stock price projections, including those for Q32 Bio Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 15, 2026 12:34 PM UTC